Michael J Zhang1, Brian E Sansbury2, Jason Hellmann2, James F Baker1, Luping Guo1, Caitlin M Parmer3, Joshua C Prenner3, Daniel J Conklin1, Aruni Bhatnagar1, Mark A Creager3, Matthew Spite2. 1. Institute of Molecular Cardiology, Diabetes and Obesity Center, Division of Cardiovascular Medicine, University of Louisville School of Medicine, Louisville, KY. 2. Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Harvard Institutes of Medicine, Boston, MA. 3. Vascular Medicine Section, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Resolvins are lipid mediators generated by leukocytes during the resolution phase of inflammation. They have been shown to regulate the transition from inflammation to tissue repair; however, it is unknown whether resolvins play a role in tissue revascularization following ischemia. METHODS: We used a murine model of hind limb ischemia (HLI), coupled with laser Doppler perfusion imaging, microcomputed tomography, and targeted mass spectrometry, to assess the role of resolvins in revascularization and inflammation resolution. RESULTS: In mice undergoing HLI, we identified resolvin D2 (RvD2) in bone marrow and skeletal muscle by mass spectrometry (n=4-7 per group). We also identified RvD2 in skeletal muscle biopsies from humans with peripheral artery disease. Monocytes were recruited to skeletal muscle during HLI and isolated monocytes produced RvD2 in a lipoxygenase-dependent manner. Exogenous RvD2 enhanced perfusion recovery in HLI and microcomputed tomography of limb vasculature revealed greater volume, with evidence of tortuous arterioles indicative of arteriogenesis (n=6-8 per group). Unlike other treatment strategies for therapeutic revascularization that exacerbate inflammation, RvD2 did not increase vascular permeability, but reduced neutrophil accumulation and the plasma levels of tumor necrosis factor-α and granulocyte macrophage colony-stimulating factor. In mice treated with RvD2, histopathologic analysis of skeletal muscle of ischemic limbs showed more regenerating myocytes with centrally located nuclei. RvD2 enhanced endothelial cell migration in a Rac-dependent manner, via its receptor, GPR18, and Gpr18-deficient mice had an endogenous defect in perfusion recovery following HLI. Importantly, RvD2 rescued defective revascularization in diabetic mice. CONCLUSIONS: RvD2 stimulates arteriogenic revascularization during HLI, suggesting that resolvins may be a novel class of mediators that both resolve inflammation and promote arteriogenesis.
BACKGROUND: Resolvins are lipid mediators generated by leukocytes during the resolution phase of inflammation. They have been shown to regulate the transition from inflammation to tissue repair; however, it is unknown whether resolvins play a role in tissue revascularization following ischemia. METHODS: We used a murine model of hind limb ischemia (HLI), coupled with laser Doppler perfusion imaging, microcomputed tomography, and targeted mass spectrometry, to assess the role of resolvins in revascularization and inflammation resolution. RESULTS: In mice undergoing HLI, we identified resolvin D2 (RvD2) in bone marrow and skeletal muscle by mass spectrometry (n=4-7 per group). We also identified RvD2 in skeletal muscle biopsies from humans with peripheral artery disease. Monocytes were recruited to skeletal muscle during HLI and isolated monocytes produced RvD2 in a lipoxygenase-dependent manner. Exogenous RvD2 enhanced perfusion recovery in HLI and microcomputed tomography of limb vasculature revealed greater volume, with evidence of tortuous arterioles indicative of arteriogenesis (n=6-8 per group). Unlike other treatment strategies for therapeutic revascularization that exacerbate inflammation, RvD2 did not increase vascular permeability, but reduced neutrophil accumulation and the plasma levels of tumor necrosis factor-α and granulocyte macrophage colony-stimulating factor. In mice treated with RvD2, histopathologic analysis of skeletal muscle of ischemic limbs showed more regenerating myocytes with centrally located nuclei. RvD2 enhanced endothelial cell migration in a Rac-dependent manner, via its receptor, GPR18, and Gpr18-deficientmice had an endogenous defect in perfusion recovery following HLI. Importantly, RvD2 rescued defective revascularization in diabeticmice. CONCLUSIONS: RvD2 stimulates arteriogenic revascularization during HLI, suggesting that resolvins may be a novel class of mediators that both resolve inflammation and promote arteriogenesis.
Authors: László Offertáler; Fong-Ming Mo; Sándor Bátkai; Jie Liu; Malcolm Begg; Raj K Razdan; Billy R Martin; Richard D Bukoski; George Kunos Journal: Mol Pharmacol Date: 2003-03 Impact factor: 4.436
Authors: Kip M Connor; John Paul SanGiovanni; Chatarina Lofqvist; Christopher M Aderman; Jing Chen; Akiko Higuchi; Song Hong; Elke A Pravda; Sharon Majchrzak; Deborah Carper; Ann Hellstrom; Jing X Kang; Emily Y Chew; Norman Salem; Charles N Serhan; Lois E H Smith Journal: Nat Med Date: 2007-06-24 Impact factor: 53.440
Authors: Guangbi Li; Zhida Chen; Owais M Bhat; Qinghua Zhang; Justine M Abais-Battad; Sabena M Conley; Joseph K Ritter; Pin-Lan Li Journal: J Lipid Res Date: 2017-04-12 Impact factor: 5.922
Authors: Bian Wu; Evan C Werlin; Mian Chen; Giorgio Mottola; Anuran Chatterjee; Kevin D Lance; Daniel A Bernards; Brian E Sansbury; Matthew Spite; Tejal A Desai; Michael S Conte Journal: J Vasc Surg Date: 2018-07-29 Impact factor: 4.268
Authors: Mary Caitlin P Sok; Maxianne C Tria; Claire E Olingy; Cheryl L San Emeterio; Edward A Botchwey Journal: Acta Biomater Date: 2017-02-16 Impact factor: 8.947
Authors: Jason Hellmann; Brian E Sansbury; Blenda Wong; Xiaofeng Li; Mansher Singh; Kristo Nuutila; Nan Chiang; Elof Eriksson; Charles N Serhan; Matthew Spite Journal: J Invest Dermatol Date: 2018-03-17 Impact factor: 8.551
Authors: Jeremy W Winkler; Stephania Libreros; Xavier De La Rosa; Brian E Sansbury; Paul C Norris; Nan Chiang; David Fichtner; Gregory S Keyes; Nicholas Wourms; Matthew Spite; Charles N Serhan Journal: J Leukoc Biol Date: 2018-01-29 Impact factor: 4.962